Sihpromatum - I Grew my Boobs in China: Volume 1

Product Information

There have been some changes in the adjuvant endocrinetherapy over the six time periods, the proportion of patients receiving tamoxifen endocrine therapy, and in combination with ovarian function suppression (OFS) regimens is gradually increasing, and there is a trend towards longer duration of endocrine therapy. Patient demographic characteristics and clinical features were compared among the six time periods using a trend test. Second, we did not collect data on the status of pregnancy and child birth after breast cancer diagnosis. To reduce the burden of breast cancer, China launched a national breast cancer screening program for rural female residents aged 35–59 years old in 2009 (extended to 35–64 years after 2012), as well as for urban female residents aged 40–69 years old in 2012 (later changed to 45–74 years after 2016) ( 7).

Early detection, along with available, low-cost, and effective treatment, can result in improved cancer staging upon presentation and reduced mortality. The analysis also reveals that breast cancer rates are higher in urban areas of China than in rural areas.Women with higher income showed significantly higher screening participation despite the fact that 15% of the participants did not reveal their income level. Compared with western countries, breast cancer patients in China are younger and have better cardiac status, and the incidence of cardiac adverse events caused by anthracyclines is lower, therefore, treatment options for young breast cancer should balance the cure rate and the risk of cardiotoxicity. Early staging and longer duration of endocrine therapy were factors associated with a favorable prognosis. However, later study showed that more patients in the Chinese population have CYP2D6 gene polymorphisms, of which approximately 20% have CYP2D6∗10 T/T genotype (mutant homozygote), which affects CYP2D6 enzyme activity and reduces the efficacy of tamoxifen.

Numerous factors have the potential to restrict the uptake of cancer screening in women, including but not limited to low socioeconomic status, cultural barriers, and cancer fatalism ( 9). This approval is an important advance in the way breast cancer is classified and treated in China and supports our vision to bring Enhertu to more patients worldwide. Public health authorities in China can play a crucial role in developing well-defined strategies to tackle the issue and reduce the breast cancer burden in China. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.

Stress: Stress – which is more likely to be experienced in large cities – has been linked to increased risk of developing cancer. Driven by a growing understanding of breast cancer biology, AstraZeneca is starting to challenge, and redefine, the current clinical paradigm for how breast cancer is classified and treated to deliver even more effective treatments to patients in need – with the bold ambition to one day eliminate breast cancer as a cause of death. Enhertu consists of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable link er.

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Upon conducting this study, we discovered that women who underwent health examinations were significantly more likely to obtain cancer screening even when other potential restricting factors were accounted for. I have read this warning and will not be using any of the contained product information for clinical purposes. For the final analysis, 15,354 female participants were excluded due to their age being less than 20 years old, having incomplete sociodemographic data, or lacking responses to the breast cancer screening questions. Using the population-based cohort, we estimate the epidemiological characteristics of young breast cancer in China.

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Patients eligible for enrollment were breast cancer in young women (≤35 years old) who were first diagnosed and treated at the eight centres, and patients who come to the hospital for review or re-visit due to recurrence of metastasis in the six time periods were excluded.